Monte Rosa Therapeutics (GLUE) Receivables - Other (2022 - 2026)

Monte Rosa Therapeutics' Receivables - Other history runs 5 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 227.34% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (up 227.34% YoY), while the FY2025 annual figure was $4.6 million, up 2558.96% from the prior year.
• Receivables - Other was $4.6 million for Q1 2026 at Monte Rosa Therapeutics, roughly flat from $4.6 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $7.7 million in Q4 2022 to a low of $173000.0 in Q4 2024.
• Historically, Receivables - Other has averaged $2.4 million across 5 years, with a median of $1.4 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Receivables - Other plunged 93.4% in 2023, then surged 2558.96% in 2025.
• A 5-year view of Receivables - Other shows it stood at $7.7 million in 2022, then slumped by 93.4% to $505000.0 in 2023, then sank by 65.74% to $173000.0 in 2024, then soared by 2558.96% to $4.6 million in 2025, then climbed by 0.2% to $4.6 million in 2026.
• The last three Receivables - Other figures came in at $4.6 million (Q1 2026), $4.6 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.